Sign In
Buy RARE
$22.41
+0.630 (+2.89%)
At Close: Jun 03, 2026
Philadelphia, Pennsylvania--(Newsfile Corp. - March 16, 2026) - National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Ultragenyx Pharmaceutical
Tactical Resources Signs Agreement to Acquire the Sierra Blanca Quarry and Tailings Access for the Peak Rare Earth Project
08:30am, Monday, 16'th Mar 2026
VANCOUVER, BC / ACCESS Newswire / March 16, 2026 / Tactical Resources Corp. (TSXV:RARE)(OTC PINK:USREF) ("Tactical" or the "Company"), a mineral exploration and development company, is pleased to anno
NEW YORK, March 15, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August
New class action for Ultragenyx (RARE) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 4/6/2026.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Ultragenyx To Contact Him Directly To Discuss Their Options If you purchased or acqui
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Ultragenyx To Contact Him Directly To Discuss Their Options
Ultragenyx Pharmaceutical Inc. $RARE Shares Sold by B Group Inc.
03:07am, Saturday, 14'th Mar 2026
B Group Inc. reduced its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) by 24.0% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchan
NEW YORK and NEW ORLEANS, March 13, 2026 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Ultragenyx P
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm
09:34am, Friday, 13'th Mar 2026
LOS ANGELES, March 13, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ultragenyx Pharmaceutical Inc.
SAN DIEGO, March 13, 2026 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces purchasers or acquirers of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) common stock between Augus
RARE's DTX301 Meets First Key Goal in Phase III OTC Deficiency Study
09:27am, Friday, 13'th Mar 2026
Ultragenyx Pharmaceutical reports phase III success for DTX301 in OTC deficiency, lowering ammonia 18% compared to placebo and keeping levels normal through 36 weeks.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Ultragenyx To Contact Him Directly To Discuss Their Options
New York, New York--(Newsfile Corp. - March 12, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) betw
NEW YORK, March 12, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August
Ultragenyx's Gene Therapy Study Shows Ammonia Reduction In Rare Metabolic Disorder
01:35pm, Thursday, 12'th Mar 2026
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) shares are down on Thursday as the company reported data from its Phase 3 study of DTX301, a gene therapy for ornithine transcarbamylase (OTC) deficiency.
